OvaScience shareholders have an opportunity to recover their investment losses. Click "Join this Class Action" above.
Rosen Law Firm announces the filing of a securities class action lawsuit on behalf of purchasers of OvaScience, Inc. securities (NASDAQ: OVAS) pursuant to and/or traceable to the Registration Statement and Prospectus issued in connection with OvaScience’s January 8, 2015 Secondary Offering, resulting from allegations that Cigna may have issued materially misleading business information to the investing public.
If you purchased shares of OvaScience pursuant to and/or traceable to OvaScience’s January 8, 2015 Secondary Offering and would like to join the action, please click "Join This Class Action" above.
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against OvaScience, Inc. – OVAS
New York, N.Y., February 10, 2016. Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of OvaScience, Inc. securities (NASDAQ: OVAS) pursuant to and/or traceable to the Registration Statement and Prospectus issued in connection with OvaScience’s January 8, 2015 Secondary Offering (the “Offering”). The lawsuit seeks to recover damages for OvaScience investors under the federal securities laws.
To join the OvaScience class action, go to the firm’s website at http://rosenlegal.com/cases-820.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email email@example.com or firstname.lastname@example.org for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, the documents filed in connection with the Offering contained materially false and misleading statements and omissions, including that the approximately 150 patients that had received OvaScience’s AUGMENT procedure in 2014 did not achieve a pregnancy success rate that was significantly higher than the rate achieved without its AUGMENT procedure. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-820.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at email@example.com or firstname.lastname@example.org.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827